Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):359–364. doi: 10.1111/j.1365-2125.1986.tb05207.x

Comparison of the acute vascular effects of frusemide and bumetanide.

G D Johnston, D P Nicholls, G B Kondowe, M B Finch
PMCID: PMC1400942  PMID: 3518770

Abstract

The acute peripheral vascular and diuretic effects of intravenous frusemide 10 mg and 20 mg were compared with those of bumetanide 250 micrograms and 500 micrograms in a group of 10 salt depleted volunteers. Significant reductions in forearm blood flow (FBF) were observed after frusemide 10 mg (-0.77 ml 100 ml-1 min-1 P less than 0.05) and 20 mg (-0.75 ml 100 ml-1 min-1 P less than 0.01 at 15 min). No changes were observed after bumetanide. The reductions in blood flow produced by frusemide were significantly different from those of bumetanide (P less than 0.05) at 15 min. Increases in venous capacitance (VC) and mean arterial blood pressure (MAP) were observed after frusemide but these differences were not statistically different from placebo or bumetanide. No increases were seen after bumetanide. Plasma aldosterone concentrations were unchanged after either drug but plasma renin activity (PRA) was increased after frusemide 10 mg (4.42 +/- 1.01----8.50 +/- 1.90 ng A I ml-1 h-1 P less than 0.01) and 20 mg (4.01 +/- 0.72----7.81 +/- 2.27 ng A I ml-1 h-1 P less than 0.05). No increases were observed after bumetanide and significant differences between bumetanide and frusemide were observed (P less than 0.01). This study demonstrates that the acute peripheral arterial effects of frusemide are not observed after comparable diuretic doses of bumetanide. The differences appear to be related to the ability of the drugs to stimulate acute renin release from the kidney.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bollerup A. C., Hesse B., Sigurd B. Changes of glomerular filtration rate and renal plasma flow following intravenous bumetanide in organic heart disease. Acta Pharmacol Toxicol (Copenh) 1974 May;34(5):305–311. doi: 10.1111/j.1600-0773.1974.tb03527.x. [DOI] [PubMed] [Google Scholar]
  2. Dikshit K., Vyden J. K., Forrester J. S., Chatterjee K., Prakash R., Swan H. J. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973 May 24;288(21):1087–1090. doi: 10.1056/NEJM197305242882102. [DOI] [PubMed] [Google Scholar]
  3. Duchin K. L., Hutcheon D. E. Distribution of intracortical renal blood flow induced by bumetanide in the dog. J Pharmacol Exp Ther. 1978 Jan;204(1):135–140. [PubMed] [Google Scholar]
  4. Friedman P. A., Roch-Ramel F. Hemodynamic and natriuretic effects of bumetanide and furosemide in the cat. J Pharmacol Exp Ther. 1977 Oct;203(1):82–91. [PubMed] [Google Scholar]
  5. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  6. Imbs J. L., Schmidt M., Velly J., Schwartz J. Comparison of the effect of two groups of diuretics on renin secretion in the anaesthetized dog. Clin Sci Mol Med. 1977 Feb;52(2):171–182. doi: 10.1042/cs0520171. [DOI] [PubMed] [Google Scholar]
  7. Johnston G. D., Hiatt W. R., Nies A. S., Payne N. A., Murphy R. C., Gerber J. G. Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. Circ Res. 1983 Nov;53(5):630–635. doi: 10.1161/01.res.53.5.630. [DOI] [PubMed] [Google Scholar]
  8. Johnston G. D., Nicholls D. P., Leahey W. J., Finch M. B. The effects of captopril on the acute vascular responses to frusemide in man. Clin Sci (Lond) 1983 Oct;65(4):359–363. doi: 10.1042/cs0650359. [DOI] [PubMed] [Google Scholar]
  9. Johnston G. D., Nicholls D. P., Leahey W. J. The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmacol. 1984 Jul;18(1):75–81. doi: 10.1111/j.1365-2125.1984.tb05024.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Johnston G. D., O'Connor P. C., Nicholls D. P., Leahey W. J., Finch M. B. The effects of propranolol and digoxin on the acute vascular responses to frusemide in normal man. Br J Clin Pharmacol. 1985 Apr;19(4):417–421. doi: 10.1111/j.1365-2125.1985.tb02664.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lal S., Murtagh J. G., Pollock A. M., Fletcher E., Binnion P. F. Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures. Br Heart J. 1969 Nov;31(6):711–717. doi: 10.1136/hrt.31.6.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Olsen U. B., Ahnfelt-Ronne I. Bumetanide induced increase of renal blood flow in conscious dogs and its relation to local renal hormones (PGE, kallikrein and renin). Acta Pharmacol Toxicol (Copenh) 1976 Mar;38(3):219–228. doi: 10.1111/j.1600-0773.1976.tb03114.x. [DOI] [PubMed] [Google Scholar]
  13. Ostergaard E. H., Magnussen M. P., Nielsen C. K., Eilertsen E., Frey H. H. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung. 1972 Jan;22(1):66–72. [PubMed] [Google Scholar]
  14. Pedrinelli R., Magagna A., Arzilli F., Sassano P., Salvetti A. Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. Clin Pharmacol Ther. 1980 Dec;28(6):722–731. doi: 10.1038/clpt.1980.227. [DOI] [PubMed] [Google Scholar]
  15. Pierucci A., Simonetti B. M., Stirati G., Cinotti G. A. Effects of bumetanide upon PRA and urinary kallikrein excretion in normal subjects before and after indomethacin treatment. Minerva Nefrol. 1980 Jul-Sep;27(3):421–424. [PubMed] [Google Scholar]
  16. Ramírez A., Abelmann W. H. Hemodynamic effects of diuresis by ethacrynic acid in normal subjects and in patients with congestive heart failure. Arch Intern Med. 1968 Apr;121(4):320–327. doi: 10.1001/archinte.1968.03640040014003. [DOI] [PubMed] [Google Scholar]
  17. Sigurd B., Hesse B., Bollerup A. C., Valentin N. Investigations with intravenous bumetanide. Postgrad Med J. 1975;51 (Suppl 6):27–34. [PubMed] [Google Scholar]
  18. Velasquez M. T., Wan S. H., Maronade R. F. Bumetanide-induced rise in plasma renin activity. Clin Pharmacol Ther. 1978 Aug;24(2):186–191. doi: 10.1002/cpt1978242186. [DOI] [PubMed] [Google Scholar]
  19. WHITNEY R. J. The measurement of volume changes in human limbs. J Physiol. 1953 Jul;121(1):1–27. doi: 10.1113/jphysiol.1953.sp004926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wright B. M., Dore C. F. A random-zero sphygmomanometer. Lancet. 1970 Feb 14;1(7642):337–338. doi: 10.1016/s0140-6736(70)90709-9. [DOI] [PubMed] [Google Scholar]
  21. Ziacchi V., Rossi A., Lomanto B. Modificazioni emodinamiche indotte dalla bumetanide endovenosa nello scompenso congestizio. G Ital Cardiol. 1981;11(1):104–109. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES